



For Immediate Release

Solulink Awarded SBIR NIAID Phase I Grant for Development of a Multiplexed Vaccine Titer Assay.

San Diego, California — June 10, 2010. Solulink, Inc., a leading innovator of state-of-the-art conjugation reagents, easy-to-use reproducible linking kits, and conjugation services for the life science research, diagnostics, and pharmaceutical markets, today announced it has been awarded a \$600,000 SBIR Phase I grant from the National Institute of Allergy and Infectious Diseases (NIAID) to develop a Multiplexed Vaccine Titer Assay.

The increasing range and multivalency of vaccines has created a need for cost-effective, highly multiplexed serological testing to determine antibody response to each component. New tests are needed both as screening assays to evaluate protection of each patient and as a tool for vaccine development to detect efficacy for each target in novel combinations. Existing multiwell ELISA immunoassay protocols are laborious and poorly matched to multi-analyte testing. Solulink, in collaboration with Professor Stephen Kron and his team in the Department of Molecular Genetics and Cell Biology, University of Chicago will apply its proprietary protein multiplex technology to develop a multiplex vaccine titer test. David Schwartz, Ph.D., Solulink's Chief Science Officer and Principal Investigator for the project stated, "We are pleased that SBIR has awarded us the opportunity to demonstrate the ability of our platform technology to develop a multiplexed vaccine titer assay. With this grant we propose to develop a single assay to quantify responses to each component of a multi-analyte vaccine."

The Small Business Innovation Research Program (SBIR) works to ensure that the nation's small, high-tech, innovative businesses act as a significant part of the federal government's research and development projects. In reviewing grant applications the SBIR seeks unique research projects that are of high scientific caliber that are relevant to public health needs.

SBIR Grant 1 R43 AI91340-01



About Solulink

Solulink's proprietary conjugation reagents and easy-to-use linking kits provide unique features and benefits used to link proteins, oligonucleotides, peptides, and antibodies to each other or to a wide range of surfaces including beads, chips, and slides. Solulink has developed several lines of products that incorporate its technology including streptavidin magnetic and agarose beads that have the highest binding capacity on the market, ChromaLink Biotin with a built in quantification feature, antibody labeling kits, oligo and peptide synthesis reagents. Solulink markets its products both directly and through distributors and licensing partners worldwide. Solulink is a privately held company located in San Diego, California. For more information, please visit www.solulink.com.

Contact

Steve DeGraw

Solulink, Incorporated

9853 Pacific Heights Blvd. Suite H,

San Diego, California 92121

T 858.625.0670

F 858.625.0770

solulink@solulink.com